Wu Gang, Yu Chuanfei, Wang Wenbo, Du Jialiang, Fu Zhihao, Xu Gangling, Li Meng, Wang Lan
Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Daxing District, Beijing 102629, China.
Anal Chem. 2023 Jan 31;95(4):2548-2560. doi: 10.1021/acs.analchem.2c05071. Epub 2023 Jan 19.
Imaged capillary isoelectric focusing (icIEF) and ion-exchange chromatography (IEX) are two essential techniques that are routinely used for charge variant analysis of therapeutic monoclonal antibodies (mAbs) during their development and in quality control. These two techniques that separate mAb charge variants based on different mechanisms and IEX have been developed as front-end separation techniques for online mass spectrometry (MS) detection, which is robust for intact protein identification. Recently, an innovative, coupled icIEF-MS technology has been constructed for protein charge variant analysis in our laboratory. In this study, icIEF-MS developed and strong cation exchange (SCX)-MS were optimized for charge heterogeneity characterization of a diverse of mAbs and their results were compared based on methodological validation. It was found that icIEF-MS outperformed SCX-MS in this study by demonstrating outstanding sensitivity, low carryover effect, accurate protein identification, and higher separation resolution although SCX-MS contributed to higher analysis throughput. Ultimately, integrating our novel icIEF-HRMS analysis with the more common SCX-MS can provide a promising and comprehensive strategy for accelerating the development of complex protein therapeutics.
成像毛细管等电聚焦(icIEF)和离子交换色谱(IEX)是治疗性单克隆抗体(mAb)研发及质量控制过程中常规用于电荷变体分析的两项重要技术。这两种基于不同机制分离mAb电荷变体的技术以及IEX已被开发为用于在线质谱(MS)检测的前端分离技术,该检测对于完整蛋白质鉴定具有强大功能。最近,我们实验室构建了一种创新的耦合icIEF-MS技术用于蛋白质电荷变体分析。在本研究中,对开发的icIEF-MS和强阳离子交换(SCX)-MS进行了优化,以表征多种mAb的电荷异质性,并基于方法学验证比较了它们的结果。结果发现,尽管SCX-MS有助于提高分析通量,但在本研究中icIEF-MS表现优于SCX-MS,具有出色的灵敏度、低残留效应、准确的蛋白质鉴定和更高的分离分辨率。最终,将我们新颖的icIEF-高分辨率质谱(HRMS)分析与更常用的SCX-MS相结合,可以为加速复杂蛋白质治疗药物的开发提供一种有前景的综合策略。